Accessibility Menu
PolyNovo logo

PolyNovo(OTC) CALZF

Market Cap$428.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-11%
5 Year-59%
1 Year-26%
1 Month-9%
$0.62
+0.00%
+0.00Today
PolyNovo last closing stock price
MetricPriceDate
Last closeUSD 0.622026-08-18
PolyNovo stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.622026-08-07
1 month-8.89%USD 0.682026-07-17
3 month-19.08%USD 0.772026-05-18
Year to date-20.52%USD 0.782025-12-31
1 year-25.63%USD 0.832025-08-18
3 year-50.4%USD 1.252023-08-18
5 year-58.94%USD 1.512021-08-18
Since inception-11.43%USD 0.702003-08-08

PolyNovo Financials at a Glance

Market Cap

$428.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$253.48M

Net Income (TTM)

A$15.78M

EPS (TTM)

$0.01

P/E Ratio

68.13

Dividend

$0.00

Beta (Volatility)

-19186.78 (Low)

Price

$0.62

Volume

20

Open

$0.62

Previous Close

$0.62

Daily Range

$0.62 - $0.62

52-Week Range

$0.62 - $1.02

Estimated Earnings Date

Mar 2, 2027

CALZF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About PolyNovo

Polynovo Limited is a healthcare company specializing in the development of innovative medical devices using its patented polymer technology, NovoSorb. The company focuses on biodegradable temporizing matrix (BTM) products, primarily serving markets in the United States, Australia, New Zealand, and other regions.

Products and Services
  • Biodegradable temporizing matrix (BTM) for wound care
  • Advanced polymer technology for medical applications
  • Research and development in innovative medical devices
Growth Outlook
  • Revenue increased to AUD 70.17 million in the latest quarter
  • Gross profit margin improved to 30.57% in Q2 2025
  • Strong market demand for innovative wound care solutions
Financial Highlights
  • Net income of AUD 2,998 in Q2 2025, showing resilience
  • Current ratio of 3.03 indicates strong liquidity position
  • Trailing twelve months (TTM) revenue of AUD 246.5 million, reflecting growth
Polynovo Limited is positioned in the medical devices industry, focusing on advanced solutions for wound care. The company's innovative approach and patented technology provide a competitive edge in a growing market. Recent financial performance indicates a positive trajectory, with significant revenue growth and improved profit margins. The strong liquidity position further supports the company's ability to invest in research and development, ensuring continued innovation and market relevance. As the demand for effective wound care solutions rises, Polynovo is well-placed to capitalize on these opportunities.
AI Generated • Aug 16, 2026

Industry

Healthcare Equipment and Supplies

Employees

301

CEO

Robyn Elliott, PhD

Headquarters

Port Melbourne, VIC 3207, AU

CALZF Financials

Key Financial Metrics (TTM)

Gross Margin

32.31%

Operating Margin

1.98%

Net Income Margin

7.16%

Return on Equity

11.87%

Return on Capital

4.47%

Return on Assets

8.01%

Earnings Yield

1.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$428.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

690.84M

Volume

20

Avg. Volume

2.51K

Financials (TTM)

Gross Profit

A$117.39M

Operating Income

A$6.12M

EBITDA

A$16.50M

Operating Cash Flow

A$15.51M

Capital Expenditure

-A$26.49M

Free Cash Flow

-A$10.98M

Cash & ST Invst.

A$29.25M

Total Debt

A$31.73M

PolyNovo Performance Analysis

PolyNovo annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 30,055,725N/A
20232023-06-30AUD 43,888,23146.0%
20242024-06-30AUD 67,629,45954.1%
20252025-06-30AUD 82,406,51021.9%
PolyNovo sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3018.9%
Q22024-12-316.2%
Q42025-06-3013.8%
Q22025-12-313.6%
PolyNovo annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.00N/A
20232023-06-30AUD -0.00269.2%
20242024-06-30AUD 0.00N/A
20252025-06-30AUD 0.01153.1%
PolyNovo sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-5.1%
Q22024-12-3129.7%
Q42025-06-30197.9%
Q22025-12-31-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$70.17M

+48.8%

Gross Profit

A$21.45M

+29.2%

Gross Margin

30.57%

N/A

Market Cap

$428.32MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.42M

N/A

Employees

301

N/A

Net Income

A$3.00K

-99.9%

EBITDA

A$3.35M

+34.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$29.25M

-35.9%

Total Debt

A$31.73M

+106.9%

Accounts Receivable

A$24.20M

+70.8%

Inventory

A$11.85M

+72.0%

Long Term Debt

A$28.93M

+111.2%

Short Term Debt

A$2.80M

+71.1%

Return on Assets

8.01%

N/A

Return on Invested Capital

2.72%

N/A

Free Cash Flow

-A$1.62M

-3406.9%

Operating Cash Flow

A$9.15M

+688.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SOLTFNxera Pharma Co., Ltd.
$5.01+0.00%
CLVSFCellaVision AB (publ)
$14.00+0.00%
BOIRFBoiron S.A.
$31.50+0.00%
AVNBFAvon Technologies Plc
$22.49+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.48-0.02%
INTCIntel
$96.69-0.07%
NOKNokia
$10.39-0.04%
NVDANvidia
$219.74-0.02%

Questions About CALZF

What is the current price of PolyNovo?

PolyNovo is trading at $0.62 per share.

What is the 52-week range for PolyNovo?

Over the past 52 weeks, PolyNovo has traded between $0.62 and $1.02.

How much debt does PolyNovo have?

As of the most recent reporting period, PolyNovo reported total debt of A$11.23M.

How much cash does PolyNovo have on hand?

PolyNovo reported A$21.98M in cash and cash equivalents in its most recent financial results.

What is PolyNovo’s dividend yield?

PolyNovo does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.